Targeted Radionuclide Imaging and Therapy in Prostate Cancer

Seminar: Targeted Radionuclide Imaging and Therapy in Prostate Cancer

11 September 2021

  • RIZIV/INAMI accreditation 3 CP granted (N° 21010970; category 3)1
  • FANC/AFCN radiation protection continuing education granted:
    • 03h00 for Radiotherapists using nonencapsulated radioactive products
    • 03h00 for Nuclear medicine physicians
    • 00h30 for Radiopharmacists
  • Venue: Campus Erasme – Auditoire Claude (rez de chaussée du bât. F – F2.204) – 808 route de Lennik à 1070 Anderlecht2

1 RIZIV/INAMI accreditation for nuclear medicine physicians is available for BELNUC members only.
2 Subject to government restrictions on in-person meetings.

Start Your Registration 


Moderators: prof. dr. Patrick Flamen (Institut Jules Bordet) and prof. dr. Christophe Deroose (UZ Leuven)

09:00 – 09:05 Welcome
09:05 – 09:35 Radium-223 : latest developments and future perspectives
Dr. Kristoff Muylle (UZ Brussels / AZ Delta)
09:35 – 10:05 Molecular Imaging Prostate Cancer
Prof. dr. Karolien Goffin (UZ Leuven)
10:05– 10:35 Lu177-PSMA ligand therapy
Dr. Carlos Artigas (Institut Jules Bordet )
10:35– 11:00 Break
11:00– 11:30 Alpha-emitting radionuclides : radiopharmacy aspects
Erik de Blois (Erasmus MC Rotterdam)
11:30– 12:00 Targeted alpha therapy in prostate cancer
  Dr. Benedikt Feuerecker (Technical University of Munich)
12:00– 12:30 Discussion
Prof. dr. Patrick Flamen (Institut Jules Bordet)


Targeted Radionuclide Imaging and Therapy in Prostate Cancer

Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Europe. Although localized prostate cancer can be treated effectively in different ways, many patients progress to incurable metastatic castration-resistant prostate cancer. Diagnostic nuclear medicine techniques for imaging PSMA have been firmly established over the last years in guiding treatment decisions in prostate cancer patients. Moreover, emerging randomized clinical trial data demonstrate the critical role of targeted radionuclide therapies in managing advanced disease, improving overall survival. This seminar will cover the spectrum of diagnostic and therapeutic nuclear medicine techniques in prostate cancer.